Ratings OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.44 ^USD	-0.81%		-4.69%	-2.40%

Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI
Apr. 12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

Summary

According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ONCOCYTE CORPORATION	-2.40%	32.57M	D+
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B	B+
ARGENX SE	+0.79%	22.02B	B
BIONTECH SE	-17.84%	20.9B	B+
GENMAB A/S	-11.11%	17.85B	A-
WUXI APPTEC CO., LTD.	-42.83%	16.21B	A-
BEIGENE, LTD.	-17.63%	15.52B	B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B	C+
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders